Peptide LibraryAdamax
Also known as: Adamantane-modified Semax
Adamax (also called Adamantane-modified Semax) is a synthetic Semax analog in the ACTH fragment analog class. Proposed Semax analog with an adamantane moiety intended to increase lipophilicity and enzymatic stability while retaining melanocortin / neurotrophic pathway activity seen with Semax in preclinical models.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- ≈1033 g/mol
- Half-life
- Not established; designed for improved stability compared with Semax
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Melanocortin pathwaysBDNF-related signaling (proposed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 22
- Listed offers
- 48
- Median price per mg (peptide vials)
- $7.20/mg
- Typical $6.37–$8.70/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
- Peptide vials17 vendors · median $7.20/mg
- Sprays, route not stated8 vendors · median $7.05/mg
Research summary
Adamantane-modified Semax analog sold for nootropic research. No study of Adamax is indexed in PubMed; its proposed neurotrophic and stability benefits are design intent carried over from Semax. No FDA approval; human PK is not established.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Adamax profile summarises the published literature indexed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Adamax dosage: no established human dose
Adamax has no established human dosage. It is a semax derivative with an adamantane group added, sold for research, and no study of it in people or animals is indexed in PubMed or registered on ClinicalTrials.gov. The human doses that exist are for plain semax in Russian stroke studies: 12 mg a day in moderate and 18 mg a day in severe stroke for 5–10 days, and 6,000 mcg a day in two 10-day courses during rehabilitation.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Adamax is described by sellers as semax (an ACTH(4–10) fragment analog) with an adamantane group attached, meant to make it more fat-soluble and longer-lasting. Those claims are design intent: no published study of adamax exists, in people, animals or cells. The only human doses are for unmodified semax, used in Russian hospital stroke care, and they cannot be assumed to carry over to adamax.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Semax (not adamax) — acute hemispheric ischaemic stroke (1997)Clinical trial · Controlled clinical study of an analog: semax, the unmodified parent peptideStudied an analog, not Adamax itself | Adults in the acute period of ischaemic stroke (n=30, with 80 conventionally treated controls) | 12 mg a day (moderate stroke) or 18 mg a day (severe stroke) of semax | Not stated in the indexed abstract | Daily | 5 days (moderate) or 10 days (severe) | Faster recovery of neurological, especially motor, function reported | [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova. 1997. |
| Semax (not adamax) — rehabilitation after ischaemic stroke (2018)Clinical trial · Controlled clinical study of an analog: semax, the unmodified parent peptideStudied an analog, not Adamax itself | Adults after ischaemic stroke (n=110, semax and non-semax subgroups) | 6,000 mcg a day of semax | Not stated in the indexed abstract | Daily | Two 10-day courses 20 days apart | Higher plasma BDNF levels and better motor and Barthel scores reported | [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. |
Where sources disagree
- Adding an adamantane group changes how a peptide is absorbed, spread through the body and broken down, so a semax dose is not a dose of adamax.
- The semax doses come from acute stroke treatment in hospital. The nootropic uses adamax is sold for have no trial.
- Sellers give adamax inconsistent names and identifiers, and it has no CAS or PubChem record on this profile, so what a product contains cannot be checked against a reference.
Reconstitution
Common research vial sizes: 10 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL | 50 mcg per 0.01 mL |
| 10 mg | 1 mL | 10 mg/mL | 100 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- Reconstitute per supplier/lab SOP; commonly bacteriostatic water for lyophilized research peptide
- Injection Sites
- Abdomen (subQ)
- Concentration Example
- Example only: 10 mg vial reconstituted with 2 mL = 5 mg/mL
- Expected Onset
- Acute neuropeptide signaling effects are proposed but not clinically established
Sequence & molecular data
| Amino acid sequence | Ac-MEHFPGP-Adam-NH2 |
|---|---|
| Molecular formula | C50H69N11O11S |
| Molecular weight | ≈1033 g/mol |
| Half-life | Not established; designed for improved stability compared with Semax |
| Appearance | White to off-white lyophilized powder |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Proposed Semax analog with an adamantane moiety intended to increase lipophilicity and enzymatic stability while retaining melanocortin / neurotrophic pathway activity seen with Semax in preclinical models.
Origin
Synthetic adamantane-modified ACTH(4–10) analog.
Targets
No studies are linked to this profile.
Suggest a studyResearch statistics
1 PubMed publications · 0.0% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Adamax is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Adamax side effects
Adamax has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Human safety profile not established
- Possible headache or stimulation based on peptide class reports
- Possible irritation depending on route
Stacking
Common stacking partners
Combinations that include Adamax, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Adamax: frequently asked questions
What is Adamax?
Adamantane-modified Semax analog sold for nootropic research. No study of Adamax is indexed in PubMed; its proposed neurotrophic and stability benefits are design intent carried over from Semax. No FDA approval; human PK is not established.
What are the side effects of Adamax?
Adamax has no controlled human safety data, so its side-effect profile is not well established. Effects recorded on this profile include possible headache or stimulation based on peptide class reports and possible irritation depending on route. This is reference information, not medical advice.
How does Adamax work?
Proposed Semax analog with an adamantane moiety intended to increase lipophilicity and enzymatic stability while retaining melanocortin / neurotrophic pathway activity seen with Semax in preclinical models.
Is Adamax FDA approved?
No. Adamax is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Adamax?
Reported half-life for Adamax is Not established; designed for improved stability compared with Semax. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of Adamax?
Adamax has the sequence Ac-MEHFPGP-Adam-NH2, giving a chain of 4 amino acids. Its molecular formula is C50H69N11O11S.
What peptides are similar to Adamax?
Compounds most often compared with Adamax include Semax, N-Acetyl Semax Amidate, Selank and Cerebrolysin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
No references are listed for this profile.
Suggest a referenceRelated research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 6
This Adamax profile is compiled from published literature, public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Adamax research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →